LC/MS, LC/SQ
IndustriesPharma & Biopharma
ManufacturerWaters
Importance of the Topic
Analytical monitoring of trace N-nitrosamines in pharmaceuticals is critical due to their potential mutagenic and carcinogenic effects even at low concentrationsRegulatory agencies such as FDA and EMA enforce strict acceptable intake limits for these impurities, driving the need for sensitive, reliable, and accessible analytical methods
Objectives and Study Overview
The study aimed to develop a sensitive, cost effective UHPLC–MS workflow using a single quadrupole detector to quantify N-nitroso-atenolol in atenolol drug substance and drug productThe target quantitation limit was set at 1.5 ppm, representing 10 % of the regulatory specification limit for CPCA Category IV NDSRIs
Methodology
Sample preparation involved diluting atenolol formulations to 0.5 mg/mL and spiking with N-nitroso-atenolol at defined levelsCalibration curves were constructed in both neat solvent (0.2–150 ng/mL) and matrix (0.5–150 ng/mL) using serial dilutions
An UHPLC gradient method separated atenolol (RT 3.45 min) from N-nitroso-atenolol (RT 6.72 min) to minimize matrix interference
Quantitation employed selected ion recording on a QDa II Mass Detector in positive ESI mode
Instrumentation
- UHPLC: ACQUITY Arc QSM-R with 2.7 µm CORTECS Premier T3 column at 45 °C
- Mass detection: ACQUITY QDa II single quadrupole mass detector with ESI+
- UV monitoring: Photo Diode Array detector at 225 nm
- Software: Empower CDS for data acquisition, processing, and reporting
Main Results and Discussion
Calibration in solvent showed excellent linearity (R2 = 0.999) down to 0.2 ng/mL and in matrix (R2 = 0.996) down to 0.5 ng/mLRecoveries at the regulatory limit (15 ppm) ranged from 87–96 % in drug substance and 95–102 % in drug product, with RSD ≤ 1.9 %
At 1.5 ppm, recoveries were 71–96 % in substance and 84–95 % in product, with RSD ≤ 4.4 %
A divert valve and extension loop strategy enhanced robustness by protecting the mass detector from high concentration matrix components
Thermal and UV stress testing revealed stable N-nitroso-atenolol levels but increased N-formyl-atenolol, illustrating the method’s capability to detect related degradation products
Benefits and Practical Applications
- High sensitivity and specificity at sub-ppb levels using cost effective single quadrupole MS
- Clear chromatographic separation reduces matrix interference in complex formulations
- Streamlined regulated reporting with Empower CDS supports compliance with 21 CFR Part 11
- Applicable for routine quality control laboratories with limited access to high cost mass spectrometers
Future Trends and Applications
Expansion of single quadrupole workflows for other NDSRIs can democratize nitrosamine testing across diverse laboratoriesIntegration with automated sample preparation and data analytics will improve throughput and data integrity
Advancements in column technology and MS interfaces may further enhance sensitivity and resolution at lower cost
Conclusion
The developed UHPLC–MS method demonstrates that single quadrupole detection delivers reliable quantitation of N-nitroso-atenolol at regulatory levelsThis accessible workflow supports robust routine testing, regulatory compliance, and patient safety by enabling trace monitoring of NDSRIs in pharmaceutical formulations
References
- FDA Guidance for Industry Recommended Acceptable Intake Limits for Nitrosamine Drug Substance Related Impurities NDSRIs 2023
- FDA updates on Angiotensin II Receptor Blocker recalls 2023
- EMA CHAMPIX (Varenicline) recall due to N-Nitroso-Varenicline 2021
- Jireš J Douša M Nitrites as precursors of N-nitrosation in pharmaceutical samples A trace level analysis J Pharm Biomed Anal 2022 213 114677
- NCD-RisC Worldwide trends in hypertension prevalence Lancet 2021 398 957–980
- Kwon S et al Development and Validation of a Sensitive LC-MS/MS Method for N-Nitroso-Atenolol in Pharmaceuticals Separations 2025 12 122
- EMA Acceptable intakes established for N-nitrosamines Appendix 1 2025
- Zheng J et al Practical HPLC-MS analysis of nitrosamine NDSRIs using single quadrupole J Chromatogr A 2024 1736 465399
- Twohig M Bartlett A Wagh P Quantitation of N-Nitroso-Propranolol in Drug Substance using LC-MS/MS Waters App Note 2020
- Hoaglund Hyzer CS et al Mechanistic studies of N-formylation of Edivoxetine J Pharm Sci 2017 106 1218–1238
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.